AMPH - Amphastar Pharmaceuticals, Inc.


19.83
-1.180   -5.951%

Share volume: 740,581
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%

$21.01
-1.18
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
56%
Profitability 61%
Dept financing 32%
Liquidity 75%
Performance 53%
Company vs Stock growth
vs
Performance
5 Days
-1.98%
1 Month
-30.69%
3 Months
-26.96%
6 Months
-32.07%
1 Year
-28.20%
2 Year
-57.52%
Key data
Stock price
$19.83
P/E Ratio 
12.55
DAY RANGE
$19.81 - $21.07
EPS 
$2.10
52 WEEK RANGE
$19.81 - $31.26
52 WEEK CHANGE
-$29.33
MARKET CAP 
1.231 B
YIELD 
N/A
SHARES OUTSTANDING 
45.370 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$882,134
AVERAGE 30 VOLUME 
$525,636
Company detail
CEO: Yong F. Zhang
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs.

Recent news